{
    "nctId": "NCT01370551",
    "briefTitle": "Clinical Study of Vaginal Lactobacilli and Estriol (Gynoflor\u00ae) for Atrophic Vaginitis in Breast Cancer Patients",
    "officialTitle": "A Clinical Study of Pharmacokinetics, Efficacy and Safety of Vaginal Application of Lyophilised Lactobacilli and 0.03 mg Estriol (Gynoflor\u00ae) on Atrophic Vaginitis in Postmenopausal Breast Cancer Patients Treated With Aromatase Inhibitors",
    "overallStatus": "COMPLETED",
    "conditions": "Atrophic Vaginitis",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 16,
    "primaryOutcomeMeasure": "Serum Concentrations of Estriol (E3)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Patients with breast cancer on non-steroidal AI therapy (AI therapy start at least 6 months ago, and are scheduled to receive them during the study)\n2. Postmenopausal and age \u226552 with cessation of menses for at least 12 months\n3. Age 52 - 75 years\n4. Clinical symptoms of vaginal atrophy\n5. Vaginal pH \\> 5.0\n6. Karnofsky score \u226580%\n7. Signed Informed Consent Form together with contractual capability\n\nExclusion Criteria:\n\n1. Local or systemic use of any other sexual hormones (estrogens, progestins, androgens), 6 months before and during study\n2. Local or systemic use of phytoestrogens or products known for or taken to improve vaginal mucosal function, risk of vaginal infections, or vulvovaginal symptoms, 4 weeks before and during study\n3. Local or systemic use of any other anti-infectives, 2 weeks before and during study\n4. Use of any other vaginal medication, vaginal rinses and/or moisturizers, gels containing xylocain or other analgesic products to decrease pain during intercourse, 1 week before and during study\n5. Known or suspected hypersensitivity or intolerance to the study medications, inclusive their excipients\n6. Suspicion of or clinically manifest sexually transmitted infections (infections with Neisseria gonorrhoea, Chlamydia trachomatis, Treponema pallidum, genital herpes, Trichomonas vaginalis, genital condylomata, HIV)\n7. Clinical evidence of vaginal infections requiring extra treatment\n8. Any infections of the upper genital tract\n9. Hysterectomy\n10. Genital haemorrhage of unknown origin\n11. Malignant or pre-cancerous conditions of the uterus, vulva and/or vagina (PAP smear less than 3 years ago)\n12. Acute thrombophlebitis, thromboembolic disorders or a history of these disorders in association with previous use of oestrogen preparations\n13. Abuse of alcohol or drugs\n14. All chronic illnesses which could influence the absorption, distribution, biotransformation or elimination of the test preparation\n15. Patient has a condition or is in a situation which, in the investigator's opinion, may put the patient in significant risk, may confound the study result, or may interfere significantly with the patient's participation in the study\n16. BMI lower than 18.5 or higher than 30\n17. Patient on steroidal AIs (aromasin)\n18. Vulvo-dermatological conditions (like Lichen sclerosus, Lichen rubrus, Psoriasis)\n19. Genital prolapses\n20. Endometriosis\n21. Use of antibiotics or chemotherapeuticals which are harmful to lactobacilli\n22. Participation of patient in another investigational drug study, with the exception of treatment optimisation studies with non-steroidal aromatase inhibitors (AI)s\n23. Previous participation in this study\n24. Patient is a relative of, or staff directly reporting to the investigator\n25. Patient is an employee of the sponsor",
    "sex": "FEMALE",
    "minimumAge": "52 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}